KPC Pharmaceuticals,Inc. (SHA:600422)

Market Cap	6.59B -52.5%
Revenue (ttm)	5.80B -28.2%
Net Income	117.67M -80.6%
EPS	0.16 -80.9%
Shares Out	756.98M
PE Ratio	56.10
Forward PE	20.84
Dividend	0.30 (3.45%)
Ex-Dividend Date	Jul 30, 2025

Volume	2,395,402
Average Volume	9,425,919
Open	8.70
Previous Close	8.70
Day's Range	8.46 - 8.70
52-Week Range	8.46 - 16.30
Beta	0.11
RSI	15.49
Earnings Date	Apr 25, 2026

About KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 5,072
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600422

Financial Performance

In 2025, KPC Pharmaceuticals,Inc.'s revenue was 6.58 billion, a decrease of -21.74% compared to the previous year's 8.40 billion. Earnings were 349.94 million, a decrease of -46.00%.